Global Hydantoin Anticonvulsants Market, By Drug (Mephenytoin, Fosphenytoin, Ethotoin, Phenytoin, Other), Application (Epilepsy, Neurosurgery, Seizure Prevention, Seizure Prophylaxis During or Following Neurosurgery, Seizures, Status Epilepticus), Dosage (Powder, Injection, Others), Route of Administration (Enteral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Anticonvulsants are referred to the type of drugs which are used for treating epileptic seizures. These are frequently referred to as anti-epileptic or anti-seizure medications. Epilepsy is a chronic central nervous system (neurological) illness in which brain activity becomes aberrant, resulting in seizures or episodes of odd behaviour, feelings, and, in rare cases, loss of consciousness. Bipolar disorder, borderline personality disorder, fibromyalgia, and neuropathic pain are all treated with anticonvulsant medications. Epilepsy can strike anyone at any time and in any age group. As per the Epilepsy Society of the United Kingdom data from 2019, there are over 20 medications available for the treatment of epilepsy, including barbiturates, carboxamides, carbamates, and GABA analogues, as well as over 25 generics.
Data Bridge Market Research analyses that the hydantoin anticonvulsants market was valued at USD 208.058 million in 2021 and is expected to reach USD 280.39 million by 2029, registering a CAGR of 3.80% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug (Mephenytoin, Fosphenytoin, Ethotoin, Phenytoin, Other), Application (Epilepsy, Neurosurgery, Seizure Prevention, Seizure Prophylaxis During or Following Neurosurgery, Seizures, Status Epilepticus), Dosage (Powder, Injection, Others), Route of Administration (Enteral, Parenteral, Topical, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (US), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (US), Johnson & Johnson Private Limited (US), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
|
|
Market Opportunities
|
|
Market Definition
The pharmacological class hydantoins is mostly used to treat seizures (anticonvulsant or antiepileptic drugs). Hydantoins work by blocking the sodium channel, which is found throughout the nervous system. Sodium channels are activated, resulting in the transmission of electrical impulses and the release of neurotransmitters. Barbiturates are structurally similar to hydantoin anticonvulsants. They have a heterocyclic allantoin base.
Hydantoin Anticonvulsants Market Dynamics
Drivers
- Increasing prevalence of epilepsy
The rising prevalence of epilepsy is anticipated to influence the hydantoin anticonvulsants market's growth. Epilepsy affects roughly 50 million people globally, according to a report released by the World Health Organization (WHO) in January 2019. Furthermore, it is predicted that 2.4 million new cases of epilepsy are diagnosed each year around the world.
- Rising approval of anticonvulsant drugs
The increasing approval of anticonvulsant medicine approvals is expected to flourish the market’s growth rate during the forecast period of 2022-2029. Anticonvulsant medicine approvals from the US Food and Drug Administration (FDA) are increasing, which is boosting the hydantoin anticonvulsant market income. The FDA has authorized approximately 24 anticonvulsant medicines. The first medicine containing an active ingredient derived from marijuana was approved by the FDA in 2018 to treat rare, severe forms of epilepsy such Lennox-Gastaut syndrome and Dravet syndrome.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hydantoin anticonvulsants market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of hydantoin anticonvulsants market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hydantoin anticonvulsants market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the hydantoin anticonvulsants market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hydantoin anticonvulsants market. Additionally, side effects of hydantoin anticonvulsants such as dizziness, irritability, drowsiness, fatigue, headache, and vertigo will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This hydantoin anticonvulsants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hydantoin anticonvulsants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Hydantoin anticonvulsants market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hydantoin Anticonvulsants Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The hydantoin anticonvulsants market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the hydantoin anticonvulsants market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.
Global Hydantoin Anticonvulsants Market Scope
The hydantoin anticonvulsants market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Mephenytoin
- Fosphenytoin
- Ethotoin
- Phenytoin
- Other
Application
- Epilepsy
- Neurosurgery
- Seizure Prevention
- Seizure Prophylaxis During or Following Neurosurgery
- Seizures
- Status Epilepticus
Dosage
- Injection
- Powder
- Others
Route of Administration
- Enteral
- Parenteral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hydantoin Anticonvulsants Market Regional Analysis/Insights
The hydantoin anticonvulsants market is analysed and market size insights and trends are provided by country, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the hydantoin anticonvulsants market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the hydantoin anticonvulsants market because of the rising prevalence of epilepsy in this region. Additionally, growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hydantoin Anticonvulsants Market Share Analysis
The hydantoin anticonvulsants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hydantoin anticonvulsants market.
Some of the major players operating in the hydantoin anticonvulsants market are:
- Merck KGaA (Germany)
- Eisai Co., Ltd. (Japan)
- AstraZeneca (UK)
- Sanofi (France)
- Novartis AG (Switzerland)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- WOCKHARDT (Mumbai)
- Novo Nordisk A/S (Denmark)
- Glenmark Pharmaceuticals Limited (India)
- Cipla Inc. (US)
- Bausch Health Companies Inc. (Canada)
- Otsuka America Pharmaceutical, Inc. (US)
- Johnson & Johnson Private Limited (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Sumitomo Corporation (Japan)
- Biocon (India)
SKU-